This “watch-and-wait” approach is recommended for all prostate cancer patients who will likely die of some other cause, ...
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2024 and provided an update on the company’s recent developments.
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...
A recent study led by Cedars-Sinai researchers reveals that a growing number of older men in the U.S. with intermediate or ...
The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies, other ...
Corvus Pharmaceuticals Inc. (CRVS) announced new data highlighting the potential of ciforadenant, the Company's adenosine A2A ...
In 2023 alone, 288,300 new cases of prostate cancer will be diagnosed in the United States, according to the American Cancer ...
BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer ...
ANDROGEN deprivation therapy (ADT) has been the cornerstone of treatment for advanced castration-sensitive prostate cancer ...
Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.
Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...